Innate Pharma to Advance Lacutamab Toward Phase 3 with Sobi
MARSEILLE, France, August 10, 2026 Innate Pharma SA announced plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of...
Sézary Syndrome
Advertisement
Kyowa Kirin Reports Long-Term Survival Gains With Mogamulizumab
PRINCETON, N.J., June 30, 2026 Kyowa Kirin has announced new clinical analyses demonstrating that mogamulizumab continues to deliver meaningful...
BioInvent’s TNFR2 Antibody BI-1808 Shows Promising Responses in Advanced CTCL at EHA 2026
LUND, Sweden, June 11, 2026 BioInvent International AB presented new clinical data from its ongoing Phase 2a study evaluating...
BioInvent Reports Strong BI-1808 CTCL Responses at EHA
LUND, Sweden – May 12, 2026 BioInvent International AB announced new Phase 2a clinical data demonstrating that its investigational...
Advertisement
